Form 4 for SUPN SUPERNUS PHARMACEUTICALS, INC.
Accepted 2026-03-10 00:00:00 ET · period of report 2026-03-06 · accession 0001194020-26-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-10 | 2026-03-06 | SUPN | DEC TIMOTHY C | CFO, Senior Vice-Pres | F - Tax | $54.73 | -2,883 | 6,682 | -30% | -$157.8K |
| DM | 2026-03-10 | 2026-03-06 | SUPN | DEC TIMOTHY C | CFO, Senior Vice-Pres | M - OptEx | $0.00 | +6,000 | 8,115 | +284% | $0 |
| DM | 2026-03-10 | 2026-03-06 | SUPN | DEC TIMOTHY C | CFO, Senior Vice-Pres | M - OptEx | $0.00 | -6,000 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-06 | F | D | 1,450 | $54.73 | 8,232 | D | — | — | |
| 2 | Common | Common Stock | 2026-03-06 | M | A | 3,000 | $0.00 | 9,682 | D | — | — | |
| 3 | Common | Common Stock | 2026-03-06 | F | D | 1,433 | $54.73 | 6,682 | D | — | — | |
| 4 | Common | Common Stock | 2026-03-06 | M | A | 3,000 | $0.00 | 8,115 | D | — | — | |
| 5 | Derivative | Performance Share Unit | 2026-03-06 | M | D | 3,000 | $0.00 | 0 | D | $0.00 · — to — | 3,000 Common Stock | (F2) On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. |
| 6 | Derivative | Performance Share Unit | 2026-03-06 | M | D | 3,000 | $0.00 | 0 | D | $0.00 · — to — | 3,000 Common Stock | (F2) On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. |